Brief: Verrica Pharmaceuticals Announces First Patient Dosed In Phase 3 Program
07/01/2026 13:58
Jan 7 (Reuters) - Verrica Pharmaceuticals Inc VRCA.O: VERRICA PHARMACEUTICALS ANNOUNCES FIRST PATIENT DOSED IN PHASE 3 PROGRAM EVALUATING YCANTH® (VP-102) FOR THE TREATMENT OF COMMON WARTS VERRICA PHARMACEUTICALS INC - TORII TO FUND FIRST $40 MILLION OF PHASE 3 TRIAL COSTS Source text: ID:nGNXbR2ysQ Further company coverage: VRCA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Verrica Pharmaceuticals
See all newsVerrica Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Verrica Pharma reports wider-than-expected Q2 adj loss per share
Verrica Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Verrica Pharmaceuticals Q1 revenue rises on YCANTH demand
Brief: Verrica Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Data